(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
9 September 2011 (09.09.2011)

PCT

(10) International Publication Number
WO 2011/109298 A2

(51) International Patent Classification:

A61K 49/00 (2006.01)	*A61P 17/06* (2006.01)
C07K 16/00 (2006.01)	*C12N 9/96* (2006.01)
C07K 17/00 (2006.01)	*C12N 15/63* (2006.01)
C07H 21/00 (2006.01)	*C12N 1/21* (2006.01)
A61K 39/395 (2006.01)	*C12N 5/10* (2006.01)
A61P 35/00 (2006.01)	*C12N 1/15* (2006.01)
A61P 43/00 (2006.01)	*C12N 1/19* (2006.01)
A61P 9/00 (2006.01)	*C12N 1/00* (2006.01)
A61P 25/28 (2006.01)	*C12P 21/00* (2006.01)

(21) International Application Number:
PCT/US2011/026489

(22) International Filing Date:
28 February 2011 (28.02.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/309,494 2 March 2010 (02.03.2010) US

(71) Applicant *(for all designated States except US)*: **ABBOTT LABORATORIES** [US/US]; 100 Abbott Park Road, Abbott Park, IL 60064 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **LI, Yingchun** [CN/US]; 103 Newfield Drive, Buffalo Grove, IL 60089 (US). **GU, Jijie, James** [US/US]; 19 Crimson Drive, Shrewsbury, MA 01545 (US). **MORGAN-LAPPE, Susan** [US/US]; 5419 North Canfield Avenue, Chicago, IL 60656 (US). **CHEN, Mingjiu** [US/US]; 232 Barberry Drive, Wilmington, DE 19808 (US). **HSIEH, Chung-Ming** [US/US]; 22 Olde Field Road, Newton, MA 02459 (US).

(74) Agent: **REININGER, Irene, M.**; Abbott Laboratories, 100 Abbott Park Road, AP6A-1/D0377, Abbott Park, IL 60064 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2011/109298 A2

(54) Title: THERAPEUTIC DLL4 BINDING PROTEINS

(57) Abstract: DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and/or VEGF activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis.